An interventional study of Prismatic adaptation and electric stimulation in Stroke, Ischemic, sponsored by Istituti Clinici Scientifici Maugeri SpA. Completed at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.
Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 46th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2023, is one of 31 with no phase, and was the 60th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
Italian Society of Vascular and Endovascular Surgery · Sites in Italy
Ages 45–90
Corxel Pharmaceuticals · Sites in Italy, United States, Belgium and 18 more countries
Ages 18–90
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 227 across the 50 interventional studies, 550 across the 30 observational. Of the 40 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 81 have an industry lead sponsor. The 10 most frequent:
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
Istituti Clinici Scientifici Maugeri SpA has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Ischemic Stroke with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710028Fondazione Policlinico Universitario Agostino Gemelli IRCCSTrustworthy Artificial Intelligence for Improvement of Stroke Outcomes | 2026-11-30 |
| NCT07199322Fondazione Don Carlo Gnocchi ETSClinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. | 2026-12 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Ischemic Stroke with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to to evaluate the effect and feasibility of a rehabilitation protocol with prismatic lenses associated with tDCS, compared to a prismatic lens rehabilitation protocol associated with sham stimulation, in reducing the signs of neglect in a group of patients with spatial heminegligence following ischemic stroke of the right hemisphere.
The secondary objective is to evaluate the impact of this rehabilitation protocol on functional outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive anodic tEs combined with prismatic lenses for two weeks
Combination Product: Prismatic adaptation and electric stimulation
Patients will receive sham tEs combined with prismatic lenses for two weeks
Combination Product: Prismatic adaptation and electric stimulation
Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group
Neuropsychological outcome
Oxford Cognitive Screening (OCS): is structured in 10 subtests: picture naming (0-4); semantics (0-3); orientation (0-4); visual field (0-4); sentence reading (0-15); number writing (0-3); calculation (0-4); broken hearts (0-50); praxis (0-12); recall and recognition (0-4); trails task (0-13)
Time frame: Change from baseline OCS at 2 weeks
Neuropsychological outcome
The semi structured scale for the functional evaluation of extrapersonal neglect (0-9); high score means a worse outcome
Time frame: Change form baseline the semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks
Neuropsychological outcome
The semi structured scale for the functional evaluation of personal neglect (0-9); high score means worse outcome
Time frame: Change form baseline the semi structured scale for the functional evaluation of personal neglect at 2 weeks
Neuropsychological outcome
Bergegò Scale (0-30); high score means a better outcome
Time frame: Change from baseline the Bergegò Scale at 2 weeks.
Functional outcome
Barthel Index (0-100); high score means a better outcome
Time frame: Change from baseline the Barthel Index at 2 weeks
Ran from Mar 2023 to primary completion in Apr 2026, 37 months.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 37 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Apr 2026 and completion Dec 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituti Clinici Scientifici Maugeri SpA →